Four groups, several outcomes
A randomized, blinded study enrolled 108 older Japanese adults into morning NMN, afternoon NMN, morning placebo or afternoon placebo groups for twelve weeks. Investigators assessed sleep questionnaires, fatigue and several physical tests. Sit-to-stand performance improved in all groups. Drowsiness improved in both afternoon groups, including afternoon placebo. [1]
The afternoon NMN group had the largest reported effect sizes for sit-to-stand performance and drowsiness. The authors interpreted the findings favorably, but the improvements in placebo groups are essential context. A within-group improvement alone is not proof that timing NMN caused the change. [1]
Why timing claims are easy to overread
A headline asking for the “best time to take NMN” sounds as if the study established a universal schedule. The actual question is more limited: how did specific measurements change across four assigned groups in a selected older-adult population?
Before accepting a timing recommendation, look for the direct comparison that supports it. Was afternoon NMN better than afternoon placebo on the relevant outcome? Was it better than morning NMN? An effect size describing change within one group does not automatically answer either question.
The placebo timing arms are particularly useful. They remind readers that participation, routines, repeated testing and other aspects of an experiment can coincide with change. The exact explanation cannot be assumed, but the comparison should not disappear from the summary.
Drowsiness, sleep quality and insomnia are not interchangeable
The name of the questionnaire outcome matters. A finding on drowsiness should retain that label rather than become a claim that NMN treats insomnia or restores sleep architecture. A product promising a specific sleep benefit needs evidence for that particular benefit.
The study’s physical tests also deserve separate treatment. A sit-to-stand task is not the same as running endurance, muscle growth or everyday fatigue. Our exercise evidence article helps distinguish these functional questions.
Another older-adult NMN trial reported sleep-related secondary findings while its primary stepping endpoint was negative. Reading each study’s design prevents a collection of selective positive phrases from becoming an apparently uniform evidence base.
This timing study can help shape future research questions, but it does not supply a personal dosing schedule. If sleepiness or poor sleep is the concern, discuss the symptom itself with a qualified professional. For a product comparison, record the studied population and exact endpoint before deciding whether the citation is relevant to the promise on the label. Keep the morning and afternoon placebo results in the same notes as the corresponding NMN groups, so the comparison remains visible when revisiting a timing claim.